Havrix Nourrissons Et Enfants

Havrix Nourrissons Et Enfants is an injectable solution vaccine containing inactivated hepatitis A virus and aluminium hydroxide as adjuvant. It is supplied in a dosage form intended for intramuscular or subcutaneous administration to young infants and children. Marketed in the European Union, this prescription product is classified under ATC code J07BC01 and is used to stimulate active immunity against hepatitis A infection through vaccination safely.

Havrix Nourrissons Et Enfants is indicated for the prevention of hepatitis A infection in pediatric populations.

- Primary immunisation schedule for infants as recommended by national immunisation programmes. - Booster doses for children who have completed the initial series. - Use in outbreak settings to protect susceptible children. - Administration to children with underlying chronic liver disease to reduce risk of severe hepatitis A. - Integration with other routine childhood vaccines when scheduling immunisations. - Option for subcutaneous administration when intramuscular injection is not feasible.

The safety profile of Havrix Nourrissons Et Enfants reflects the typical reactions observed with inactivated viral vaccines.

Common: - Mild pain, redness or swelling at the injection site. - Low‑grade fever lasting 24‑48 hours. - Transient fatigue or irritability. - Headache or mild muscle aches. - Nausea or mild gastrointestinal discomfort.

Serious: - Allergic reaction such as urticaria, angioedema or anaphylaxis. - Neurological events including Guillain‑Barré syndrome, though very rare. - Persistent high fever (>39°C) lasting more than 48 hours. - Severe local reaction with extensive swelling or necrosis. - Seizures or convulsions, extremely uncommon.

Before administering Havrix Nourrissons Et Enfants, healthcare providers should review the child’s medical history and consider specific precautionary measures.

- Known hypersensitivity to any vaccine component, especially aluminium hydroxide. - History of severe allergic reaction to a previous dose of hepatitis A vaccine. - Moderate or severe acute illness with fever at the time of vaccination. - Immunocompromised conditions that may affect vaccine response. - Pregnancy or breastfeeding status of the mother, if applicable. - Use in children with chronic liver disease should be evaluated by a specialist.

Havrix Nourrissons Et Enfants may interact with other medicines or vaccines; awareness of potential interactions helps ensure safe administration.

Avoid: - Concurrent administration with live‑attenuated vaccines (e.g., measles‑mumps‑rubella) unless spaced appropriately. - Simultaneous use of immunoglobulin products that could neutralise the vaccine antigen.

Use with caution: - Administration with other inactivated vaccines at the same visit; monitor for increased local reactions. - Use in children receiving immunosuppressive therapy; antibody response may be reduced. - Co‑administration with antipyretics may mask fever, but does not affect immunogenicity.